Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another View: Understanding the disease, standard of care, current treatment paradigm and the unmet need in treating Melamoma with a focus on IOVA's LN-145

Ticker(s): IOVA

Who's the expert?

An oncologist who specializes in treating melamona

Interview Questions
Q1.

Please describe your current practice, roughly how many patients with melanoma do you currently manage?

Added By: c_admin
Q2.

What is your current firstline treatment option for melanoma?

Added By: c_admin
Q3.

What are your thoughts on TIL therapy in this space, particularly Iovance's LN-145?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.